אבוסינאגיס 100 מ"ג
abbvie biopharmaceuticals ltd, israel - palivizumab 100 mg - powder for solution for injection - palivizumab - is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (rsv). safety and efficacy were established in infants with bronchopulmonary dysplasia (bpd) and in infants with a history of prematurity (35 weeks gestational age) and in children less then 2 years of age,with haemodynamically significant congenital heart disease.
אבוסינאגיס 50 מ"ג
abbvie biopharmaceuticals ltd, israel - palivizumab 50 mg - powder for solution for injection - palivizumab - is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (rsv). safety and efficacy were established in infants with bronchopulmonary dysplasia (bpd) and in infants with a history of prematurity (35 weeks gestational age) and in children less then 2 years of age,with haemodynamically significant congenital heart disease.
סינגיס
astrazeneca (israel) ltd - palivizumab - תמיסה להזרקה - palivizumab 100 mg/ml - palivizumab